fr en

Reagents and instruments for immunology, cell biology and molecular biology.

(-)-Epigallocatechin Gallate [989-51-5]

Print

Cat# HY-13653-50mg

Size : 50mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description

(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma^[1]^[2]^[3]^[4].

IC₅₀ & Target^[1]

EGFR

HER2

HER3

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	112 μM Compound: EGCG	Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry Antiadipogenic activity in mouse 3T3L1 cells assessed as differentiation of preadipocytes to adipocytes after 8 days by spectrophotometry	[PMID: 23628332]
3T3-L1	IC₅₀	25 μM Compound: EGCG, (-)-epigalocatechin gallate	Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells Inhibition of G6PD-mediated NADPH production in mouse 3T3-L1 cells	[PMID: 18313308]
A-431	EC₅₀	266 μM Compound: 1, EGCG	Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A-431	EC₅₀	38 μM Compound: 1, EGCG	Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A549	IC₅₀	185 μM Compound: EGCG	Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human A549 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
A549	IC₅₀	29 μM Compound: EGCG	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	IC₅₀	33 μM Compound: EGCG	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
CHO	IC₅₀	271 μM Compound: EGCG	Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against wild type CHO cells after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
CHO	IC₅₀	3.2 μM Compound: EGCG	Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against CHO cells expressing OATP1B3 haplotype 1 after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
CHO	IC₅₀	7.7 μM Compound: EGCG	Cytotoxicity against CHO cells expressing OATP1B11b after 48 hrs by fluorescence based CellTiter-Glo assay Cytotoxicity against CHO cells expressing OATP1B11b after 48 hrs by fluorescence based CellTiter-Glo assay	[PMID: 23327877]
COLO 201	IC₅₀	38 μM Compound: EGCG	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
CV-1	IC₅₀	12.05 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P27 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	12.27 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P2 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	12.47 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P22 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	12.48 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P11 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	12.5 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P12 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	12.5 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells Antiviral activity against Human herpesvirus 2 isolate P47 infected in African green monkey CV1 cells	[PMID: 18195068]
CV-1	IC₅₀	25 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells Antiviral activity against Human herpesvirus 2 strain 333 strain 333 infected in African green monkey CV-1 cells	[PMID: 18195068]
H9	EC₅₀	7 μg/mL Compound: 8	Inhibition of HIV-1 replication in H9 (human lymphoma) cells. Inhibition of HIV-1 replication in H9 (human lymphoma) cells.	10.1016/0960-894X(96)00095-9
H9	IC₅₀	8 μg/mL Compound: 8	Inhibition of uninfected H9 lymphocytic cell growth Inhibition of uninfected H9 lymphocytic cell growth	10.1016/0960-894X(96)00095-9
HCT-116	IC₅₀	161 μM Compound: EGCG	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 12880319]
HCT-116	IC₅₀	5 μM Compound: 54	Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as decrease in cell growth incubated for 24 hrs by MTS assay	[PMID: 33445154]
HeLa	IC₅₀	1.08 μM Compound: 4, EGCG	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol	[PMID: 22413845]
HeLa	IC₅₀	1.18 μM Compound: 4, EGCG	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol	[PMID: 22413845]
HL-60	IC₅₀	9.4 μM Compound: EGCG	Antiproliferative activity against human HL60 cells after 3 days Antiproliferative activity against human HL60 cells after 3 days	[PMID: 18693020]
HSC-T6	IC₅₀	29.8 μM Compound: EGCG	Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell viability	[PMID: 25322455]
HSC-T6	IC₅₀	31.6 μM Compound: (-)-EGCG	Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay Inhibition of cell proliferation of activated rat HSC-T6 cells incubated for 24 hrs by MTT assay	[PMID: 28257196]
HSC-T6	IC₅₀	9.9 μM Compound: EGCG	Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay Antiproliferative activity against rat HSC-T6 cells after 48 hrs by MTT assay	[PMID: 18052323]
HSC-T6	IC₅₀	9.9 μM Compound: EGCG	Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay Antifibrotic activity against rat HSC-T6 cells assessed as inhibition of proliferation after 48 hrs by BrdU incorporation assay	[PMID: 21504848]
HT-22	IC₅₀	23.8 μM Compound: 42; EGCG	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	60 μM Compound: EGCG	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Huh-7	IC₅₀	20 μM Compound: 5, EGCG	Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay Antiviral activity against HCV genotype 1a assessed as inhibition of viral entry into Huh7 cells treated for 2 hr followed by 28 hrs incubation period in compound-free medium by immunofluorescence assay	[PMID: 25103601]
Jurkat	IC₅₀	1 μM Compound: (-)-EGCG	Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate after 90 mins by fluorometric analysis	[PMID: 30776692]
Jurkat	IC₅₀	18 μM Compound: (-)-EGCG	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Arg-AMC as substrate preincubated for 12 hrs followed by addition of substrate and measured after 2 hrs by fluoro	[PMID: 30776692]
L1210	IC₅₀	690 μM Compound: EGCG	Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay Cytotoxicity against mouse L1210 cells after 24 hrs by WST8 assay	[PMID: 18951028]
L929	IC₅₀	82.3 μM Compound: EGCG	Cytotoxicity against mouse L929 cells after 3 days by MTS assay Cytotoxicity against mouse L929 cells after 3 days by MTS assay	[PMID: 25985195]
LN-229	IC₅₀	15 μM Compound: EGCG	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LX-2	CC₅₀	>100 μM Compound: EGCG	Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay Cytotoxicity against human LX2 cells assessed as cell death incubated for 24 hrs by MTT assay	[PMID: 34610571]
MCF7	IC₅₀	4 μM Compound: EGCG	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 30048133]
MCF7	IC₅₀	74 μM Compound: 38; ECGC	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 31663736]
MCF7	IC₅₀	74 μM Compound: EGCG, 38	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 25141341]
MDA-MB-231	IC₅₀	149 μM Compound: 1; EGCG	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 37776575]
MDA-MB-231	IC₅₀	76.1 μM Compound: EGCG	Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay	[PMID: 25453798]
MDA-MB-231	IC₅₀	83 μM Compound: EGCG	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDCK	CC₅₀	>100 μM Compound: EGCG	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 36521178]
MDCK	CC₅₀	>200 μM Compound: EGCG	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31954881]
MDCK	CC₅₀	275 μM Compound: 1, EGCG	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18547804]
MDCK	CC₅₀	275.4 μM Compound: 56; EGCG	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 28118010]
MDCK	EC₅₀	94.6 μM Compound: 1, EGCG	Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells Antiviral activity against Influenza A/PR8/34(H1N1)) in dog MDCK cells	[PMID: 18547804]
MDCK	ED₅₀	8.3 μM Compound: 3, EGCG	Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR	[PMID: 22115591]
MDCK	IC₅₀	41.25 μM Compound: 1, EGCG	Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay Antiviral activity against Influenza A virus (A/Memphis/1/71(H3N2)) in MDCK cells after 16 hrs by focus forming assay	[PMID: 17420124]
MEF	GI₅₀	14 μM Compound: 34, EGCG	Growth inhibition of Pin1-deficient MEF Growth inhibition of Pin1-deficient MEF	[PMID: 23796453]
MEF	GI₅₀	7 μM Compound: 34, EGCG	Growth inhibition of MEF expressing Pin1 Growth inhibition of MEF expressing Pin1	[PMID: 23796453]
NCI-H1299	IC₅₀	>80 μM Compound: EGCG	Antiproliferative activity in human NCI-H1299 cells after 72 hrs Antiproliferative activity in human NCI-H1299 cells after 72 hrs	[PMID: 29530347]
NCI-H1299	IC₅₀	20.6 μM Compound: EGCG	Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1299 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H1650	IC₅₀	24.8 μM Compound: EGCG	Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1650 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H1703	IC₅₀	17.1 μM Compound: EGCG	Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1703 cells expressing FASN assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
NCI-H460	IC₅₀	18 μM Compound: EGCG	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PANC-1	IC₅₀	62 μM Compound: EGCG	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-12	IC₅₀	0.03 μM Compound: 69; (-)-EGCG	Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry Neuroprotective activity against rat PC12 cells assessed as decrease in H2O2-induced intracellular Ca2+ level preincubated for 12 hrs followed by H2O2-stimulation and measured after 12 hrs by Fluo-3 AM dye based flow cytometry	[PMID: 38295689]
PC-9	IC₅₀	77.4 μM Compound: EGCG	Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay Antiproliferative activity against human PC9 cells harboring FASN expression and EGFR delE746-A750 mutant assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 31422225]
Peritoneal macrophage cell	IC₅₀	436.3 μM Compound: 1, EGCG	Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by Alamar blue assay	[PMID: 24106750]
RAW264.7	IC₅₀	29.8 μM Compound: EGCG	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells after 5 days	[PMID: 21456521]
Sf9	IC₅₀	0.5 μM Compound: 9, EGCG	Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil	[PMID: 25406944]
SH-SY5Y	EC₅₀	39.87 nM Compound: EGCG	Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release	[PMID: 19138859]
SK-BR-3	EC₅₀	100 μM Compound: 1, EGCG	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	EC₅₀	195 μM Compound: 1, EGCG	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	IC₅₀	149 μM Compound: 4, EGCG	Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 22559865]
SK-BR-3	IC₅₀	150 μM Compound: 27, EGCG	Cytotoxicity against human SKBR3 cells Cytotoxicity against human SKBR3 cells	[PMID: 21726077]
SK-BR-3	IC₅₀	4 μM Compound: EGCG	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 30048133]
SK-MEL-2	IC₅₀	31 μM Compound: EGCG	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SW480	IC₅₀	195 μM Compound: EGCG	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 12880319]
T47D	IC₅₀	57 μM Compound: EGCG	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T98G	IC₅₀	166 μM Compound: EGCG	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
U-266	IC₅₀	23.2 μM Compound: 52; EGCG	Induction of nitric oxide production in human U266 cells Induction of nitric oxide production in human U266 cells	[PMID: 31330448]
U-87MG ATCC	IC₅₀	18 μM Compound: EGCG	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-937	IC₅₀	1 μM Compound: 4, EGCG	Inhibition of telomerase in human U937 cells Inhibition of telomerase in human U937 cells	[PMID: 22413845]
Vero	IC₅₀	16 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P32 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	18.3 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P56 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	45.36 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P25 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	48.18 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P38 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	48.41 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P15 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	49.09 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 isolate P42 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]
Vero	IC₅₀	72.3 μM Compound: (-)-EGCG	Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer Antiviral activity against Human herpesvirus 1 F1 infected in African green monkey vero cells assessed as reduction in viral titer	[PMID: 18195068]

In Vitro

(-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner^[1].
(-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression^[1].
(-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration^[1].
(-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)^[2].
(-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase^[3].
(-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	FB-2 and WRO cells (serum-starved for 48h)
Concentration:	10, 40, 60 μM.
Incubation Time:	4 days
Result:	Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).

Western Blot Analysis^[1]

Cell Line:	FB-2 cells
Concentration:	10, 40, 60 μM.
Incubation Time:	24 h
Result:	Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2. Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.

Cell Migration Assay ^[1]

Cell Line:	FB-2 and WRO cells (serum-starved for 48h)
Concentration:	10, 40, 60 μM.
Incubation Time:	12 h
Result:	Reduced migration activity in FB-2 and WRO cells.

RT-PCR^[4]

Cell Line:	Mouse primary osteoblasts (1 ng/ml LPS-treated)
Concentration:	30 μM
Incubation Time:	3, 6, 12, 24 h
Result:	Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.

In Vivo

(-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth^[3].
(-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Orthotopic transplant BALB/c nude mice model^[3]
Dosage:	5, 10, and 20 mg/kg, once daily for 14 days.
Administration:	Intragastrical administration.
Result:	Inhibited tumors growth with no liver or lung metastases.

Animal Model:	Model of experimental periodontitis, LPS (25 μg/mouse)^[4]
Dosage:	0.5 mg/mouse, a single dose.
Administration:	Injected into the mouse lower gingiva
Result:	Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.

Molecular Weight

458.37

Formula

C₂₂H₁₈O₁₁

CAS No.

989-51-5

Appearance

Solid

Color

Off-white to pink

SMILES

O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 70 mg/mL (152.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1816 mL	10.9082 mL	21.8164 mL
5 mM	0.4363 mL	2.1816 mL	4.3633 mL
10 mM	0.2182 mL	1.0908 mL	2.1816 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC/saline water
Solubility: 10 mg/mL (21.82 mM); Suspended solution; Need ultrasonic

Purity & Documentation

Purity: 99.75%

Data Sheet (286 KB) SDS (396 KB)

COA (256 KB) HNMR (198 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1. [Content Brief]

[2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4. [Content Brief]

[3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53. [Content Brief]

[4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

HY-14590-50mg

Kaempferol [520-18-3]

50mg

HY-13653-100mg

(-)-Epigallocatechin Gallate [989-51-5]

100mg

HY-14590-100mg

Kaempferol [520-18-3]

100mg

(-)-Epigallocatechin Gallate [989-51-5]

Cat# HY-13653-50mg

Contact local distributor :

Brand : MedChemExpress

Contact local distributor :

(-)-Epigallocatechin Gallate Related Antibodies

You might also be interested by the following products: